<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01770431</url>
  </required_header>
  <id_info>
    <org_study_id>HE-201101</org_study_id>
    <nct_id>NCT01770431</nct_id>
  </id_info>
  <brief_title>Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy</brief_title>
  <official_title>A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qidong Gaitianli Medicines Co., Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and
      metastasis of hepatocarcinoma after radical hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Paralleled control Clinical Study Investigating Huaier Granule
      for Prevention of Recurrence and Metastasis of Hepatocarcinoma after Radical Hepatectomy,to
      evaluate the efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 6 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 6 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 14 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 14 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 22 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 22 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 34 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 34 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 46 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 46 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 58 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 58 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 70 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 70 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 82 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 82 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and occurrence time of recurrence and metastasis after hepatectomy</measure>
    <time_frame>Week 94 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At week 94 after took medicine, assess incidence and occurrence time of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative survival period</measure>
    <time_frame>Week 6,14,22,34,46,58,70,82,94 after took medicine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess Postoperative survival period; Eastern Cooperative Oncology Group(ECOG) and quality of life questionnaire(QLQ)-C30 scores;Imaging assessment;Alpha-fetoprotein quantitation and related biochemical indicators, etc at week 6,14,22,34,46,58,70,82,94 after took medicine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Hepatic Carcinoma;</condition>
  <arm_group>
    <arm_group_label>Huaier Granule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bank-control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
    <arm_group_label>Huaier Granule group</arm_group_label>
    <arm_group_label>Bank-control group</arm_group_label>
    <other_name>Huaier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: ≥ 18 and ≤ 75 years, both male and female;

          -  Radical hepatectomy has been performed for hepatocellular carcinoma;

          -  The hepatocellular carcinoma has been confirmed by pathological examination;

          -  Barcelona clinic liver cancer(BCLC) stage A or B;

          -  Not receiving any preoperative anticancer drug;

          -  The liver and kidney function satisfies the following conditions within 15 days after
             surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic
             transaminase(ALT)&lt;3 upper limit of normal(ULN), total bilirubin≤2ULN, serum
             creatinine &lt;1.5 ULN;

          -  Other laboratory tests meet the following requirements within 15 days after surgery
             (excluding day 15): Hb≥9g/dl, platelet count≥60×109/L, absolute neutrophil
             count&gt;1.0×109/L;

          -  The expected survival time ≥ 12 weeks;

          -  The subjects volunteer to sign the informed consent.

        Exclusion Criteria:

          -  Hepatocellular carcinoma patients who received non-radical hepatectomy;

          -  Non-hepatocellular carcinoma patients;

          -  Those with Child-Pugh C;

          -  Pregnant or lactating women;

          -  Those with active bleeding due to various reasons;

          -  Those with HIV infection or AIDS-associated diseases;

          -  Those with severe acute and chronic diseases;

          -  Those with severe diabetes;

          -  Those with serious infectious diseases;

          -  Those who can not take drugs by oral route;

          -  Drug abusers or those with psychological or mental diseases that may interfere with
             study compliance;

          -  Conditions that are considered not suitable for this study investigators
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 20, 2013</lastchanged_date>
  <firstreceived_date>January 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huaier Granule;</keyword>
  <keyword>After radical hepatectomy;</keyword>
  <keyword>Prevention of Recurrence and Metastasis;</keyword>
  <keyword>Safety.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
